

# What is Population Health AI?

Shiva Kaul (CAB, TIDE)



Anjum Khurshid (HPHCI)

Matti Hautala (HPHCI)

Geoffrey Gordon (Carnegie Mellon)

Sriram Vishwanath (Georgia Tech)

Kaan Kale (Georgia Tech)

Ege Tanrivierdi (Georgia Tech)

Min-Gyu Kim (Ajou University, Korea)

Philip Huang (Dallas County HHS)


Jiahao Yang (Harvard TH Chan)

Sijie Zhao (Harvard TH Chan)

# AI

## AI in Population Health

applying AI to automate or refine processes within current workflows.



# PH

# Processing Electronic Case Reports with Generative AI



**CAB**  
CENTER FOR AI AND BIOMEDICAL INFORMATICS



**DCHHS**  
Dallas County Health and Human Services



**HARVARD**  
**T.H. CHAN**


| Condition category                        | Number of conditions | Condition Name (s)   |
|---|----------------------|--|
| <b>Birth Defects and Infant Disorders</b> | 58                   | Anencephaly; Anophthalmia; Anotia; Aortic Valve Stenosis; Atrial Septal Defect; Atrioventricular septal defect (Endocardial cushion defect); Biliary Atresia; Bladder Exstrophy; Choanal Atresia; Cleft Lip Alone; Cleft Lip with Cleft Palate; Cleft Palate Alone; Cloacal Exstrophy; Clubfoot; Coarctation of the Aorta; Congenital cytomegalovirus (cCMV) Infection and Disease; Congenital Posterior Urethral Valves; Cystic Fibrosis; Diaphragmatic Hernia; Double Outlet Right Ventricle (DORV); Down Syndrome; Ebstein Anomaly; Encephalocele; Esophageal Atresia/Tracheoesophageal Fistula; Fetal Alcohol Spectrum Disorders; Galactosemia; Gastroschisis; Homocystinuria; Hypoplastic Left Heart Syndrome (HLHS); Hypospadias; Infant Hearing Loss; Interrupted Aortic Arch; Limb Reduction; Medium-chain Acyl-CoA Dehydrogenase Deficiency; Microphthalmia; Microtia; Neonatal Abstinence Syndrome; Omphalocele; Phenylketonuria; Primary Congenital Hypothyroidism; Pulmonary Valve Atresia and Stenosis; Rectal and Large Intestinal Atresia and Stenosis; Renal Agenesis and Hypoplasia; Severe Combined Immunodeficiency; Sickle Cell Anemia (Hemoglobin SS Disease); Single Ventricle; Small Intestinal Atresia and Stenosis; Spina Bifida; Spinal Muscular Atrophy; Tetralogy of Fallot (TOF); Total Anomalous Pulmonary Venous Connection (TAPVC); Transposition of the Great Arteries (TGA); Tricuspid Valve Atresia and Stenosis; Trisomy 13; Trisomy 18; Truncus Arteriosus (Common Truncus); Ventricular Septal Defect; X-linked Adrenoleukodystrophy |
| <b>Bloodborne Diseases</b>                | 6                    | Hepatitis B Virus Infection; Hepatitis B Virus Infection, Perinatal; Hepatitis C Virus Infection; Hepatitis C Virus Infection, Perinatal; Hepatitis D Virus Infection; Hepatitis G Virus Infection   |
| <b>Cancer</b>                             | 1                    | Cancer   |
| <b>Enteric Diseases</b>                   | 22                   | Amebiasis; Campylobacteriosis; Cholera; Clostridioides difficile (C. diff) infection; Clostridium perfringens Infection; Cryptosporidiosis; Cyclosporiasis; Giardiasis; Hemolytic uremic syndrome (HUS); Hepatitis A Virus infection; Hepatitis E Virus infection; Listeriosis; Non-pestis Yersiniosis; Non-Polio Enterovirus Infection; Norovirus Infections; Rotavirus Disease; S. Paratyphi Infection; S. Typhi Infection; Salmonellosis; Shiga toxin-producing Escherichia coli (STEC) infection; Shigellosis; Vibriosis   |
| <b>Healthcare-Associated Events</b>       | 16                   | Candida auris infection; Candidemia; Carbapenemase-Producing Organisms (CPO); Carbapenem-resistant Acinetobacter baumannii (CRAB); Carbapenem-resistant Enterobacteriaceae (CRE); Carbapenem-resistant Pseudomonas aeruginosa (CRPA); Catheter-associated Urinary Tract Infection (CAUTI); Central Line- associated Bloodstream Infection (CLABSI); Staphylococcus aureus Infection; Surgical Site Infection (SSI); Vaccine Adverse Event; Vaccinia Disease or Adverse Event; Vancomycin-intermediate Staphylococcus aureus (VISA); Vancomycin- resistant Enterococci (VRE) Infection; Vancomycin-resistant Staphylococcus aureus (VISA); Ventilator-associated Event (VAE)  |
| <b>Injuries, NEC</b>                      | 7                    | Animal Bite Injury; Drowning and Submersion; Drug Overdose and Poisoning, Non-opioid; Firearm-related injury; Head Injury; Motor Vehicle Injury; Suicide   |
| <b>Neurological Diseases</b>              | 7                    | Acute Flaccid Myelitis (AFM); Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD); Encephalitis; Guillain-Barré Syndrome; Meningitis; Parkinson's disease; Prion Disease (Human)  |
| <b>Parasitic Diseases</b>                 | 3                    | Echinococcosis; Scabies; Strongyloidiasis  |

|   |    |  |
|---|----|--|
| <b>Respiratory Conditions (infectious)</b>      | 16 | Blastomycosis; Coccidioidomycosis; COVID-19; Cryptococcosis; Hansen's disease; Histoplasmosis; Influenza-like Illness (ILI); Legionellosis; Middle East Respiratory Syndrome (MERS); Nontuberculous Mycobacteria Infection, Pulmonary; Psittacosis; Respiratory Syncytial Virus (RSV); Respiratory Syncytial Virus (RSV)-Associated Mortality; Severe Acute Respiratory Syndrome (SARS); Tuberculosis; Tuberculosis, Latent Infection (LTBI)   |
| <b>Respiratory Conditions (non-infectious)</b>  | 7  | Asbestosis; Byssinosis; Chemical Pneumonitis; Coal Workers' Pneumoconiosis (CWP); Farmer's Lung; Silicosis or pneumoconiosis due to dust containing silica; Work-related Asthma (WRA)  |
| <b>Sexually Transmitted Diseases</b>            | 13 | Chancroid; Chlamydia trachomatis infection; Genital Warts; Gonorrhea; Granuloma Inguinale (Donovanosis); Herpes, Genital; Herpes, Neonatal; HIV Infection or AIDS; Nongonococcal Urethritis; Ophthalmia Neonatorum; Pelvic Inflammatory Disease; Syphilis; Syphilis, Congenital  |
| <b>Streptococcal Diseases</b>                   | 3  | Rheumatic Fever; Streptococcal disease, invasive, Group A; Streptococcal disease, invasive, Group B  |
| <b>Systemic Conditions</b>                      | 6  | Invasive Cronobacter Infection Among Infants; Kawasaki Disease; Methemoglobinemia; Multisystem Inflammatory Syndrome in Adults (MIS-A); Multisystem Inflammatory Syndrome in Children (MIS-C); Reye's Syndrome   |
| <b>Toxic Effect of Non-Medicinal Substances</b> | 16 | Agricultural Chemicals (Fertilizer) Poisoning; Arsenic Exposure and Toxicity; Botulism; Botulism, Infant; Cadmium Exposure and Toxicity; Carbon Monoxide Poisoning; Cyanobacteria And Cyanotoxin Poisoning; Lead in Blood; Mercury Exposure and Toxicity; Non-Streptococcal Toxic Shock Syndrome; Opioid Overdose and Poisoning; Pesticide Related Illness or injury; Ricin Poisoning; Seafood Poisoning; Staphylococcal Enterotoxin B Poisoning; Streptococcal Toxic Shock Syndrome   |
| <b>Vaccine Preventable Diseases</b>             | 19 | Congenital Rubella Syndrome (CRS); Diphtheria; Influenza; Influenza-Associated Hospitalizations; Influenza-Associated Mortality; Influenza-associated pediatric mortality; Invasive Haemophilus Influenzae Disease; Invasive Pneumococcal Disease; Measles; Meningococcal disease; Mumps; Novel Influenza A Virus Infection; Orthopoxvirus Disease; Pertussis; Poliovirus Infection; Rubella; Smallpox; Tetanus; Varicella   |
| <b>Vectorborne Diseases</b>                     | 35 | Alpha-gal Syndrome; Anaplasmosis; Arboviral Disease [Other]; Babesiosis; Bartonellosis; California Serogroup Virus Disease; Chagas Disease; Chikungunya virus disease; Colorado tick fever; Dengue Virus Infection; Eastern equine encephalitis virus disease; Ehrlichiosis; Jamestown Canyon virus disease; Japanese encephalitis virus disease; Keystone virus disease; La Crosse virus disease; Leishmaniasis; Louse-borne relapsing fever (LBRF); Lyme disease; Lymphatic Filariasis; Malaria; Oropouche Virus Disease; Powassan virus disease; Snowshoe hare virus disease; Spotted Fever Rickettsiosis; St. Louis Encephalitis Virus Infection; Tick Paralysis; Tickborne relapsing fever (TBRF); Trivittatus virus disease; Tularemia; Typhus Fever; West Nile Virus Infection; Western equine encephalitis virus disease; Yellow fever; Zika Virus Disease |
| <b>Waterborne (not enteric)</b>                 | 5  | Acanthamoeba; Balamuthia mandrillaris Disease; Melioidosis; Naegleria fowleri Primary Amebic Meningoencephalitis; Nontuberculous Mycobacteria Infection, Extrapulmonary  |
| <b>Zoonotic Diseases</b>                        | 20 | Angiostrongyliasis; Anthrax; Baylisascariasis; Brucellosis; Cysticercosis; Diphyllbothriasis; Glanders; Hantavirus Infection; Leptospirosis; Lymphocytic Choriomeningitis; Mpox; Nipah Virus Infection; Plague; Q fever; Rabies (Human); Taeniasis; Toxoplasmosis; Trichinellosis; Vesicular Stomatitis; Viral Hemorrhagic Fever (VHF)   |





**Sep 2025: "56,500 facilities in all 50 states and three territories are actively sending electronic initial case reports to public health"**



# Harmonize, structure, monitor


## ECRBench: how well does AI do?



# AI

## AI in Population Health

applying AI to automate or refine processes within current workflows



# PH



using data, methods, and priorities of population health to improve AI

## Population Health AI



“Use data, methods, and priorities of population health to improve AI”

**Why?**

# Answering Population-Scale Health AI Questions



**CAB**  
CENTER FOR AI AND BIOMEDICAL INFORMATICS



**Georgia Institute  
of Technology**




# Population Health answers questions about groups of people.

- "Between these two cohorts, were there systematic deviations in quality of care?"
- "Given a treatment and control group, did the protocol work? (Adjust for confounders)."
- "Among these emergency department patients, select the 5 most emergent."




Population Health answers questions about groups of  $n > 20$  longitudinal patient records (time series of medical codes).





Population Health answers questions about groups of  $n > 20$   
longitudinal patient records (time series of medical codes).

**LLMs currently can't do this.**



$\sim 20$  tokens/code  $\times \sim 6000$  codes/outpatient = 120K tokens/outpatient  
Maximum input tokens to GPT-5 = 272K tokens

Can we skip text and directly, efficiently convey codes to LLMs?

"Use data, methods, and priorities of population health to improve AI"

**Why?**



Faithfully answer PH questions  
with **domain-specific engineering**

# Unifying AI and Evidence-Based Medicine



CAB  
CENTER FOR AI AND BIOMEDICAL INFORMATICS

**Carnegie Mellon**

| Model              | Med-Gemini-* [Yang et al., 2024]<br>Med-Gemini-(L,M) [Saab et al., 2024]<br>AMIE [Tu et al., 2025]<br>Med-PaLM 2 [Singhal et al., 2024]<br>Med-PaLM [Singhal et al., 2025]<br>OpenBioLLM [Pal and Sankarasubbu, 2024]<br>Me-LLaMA [Xie et al., 2024]<br>MEDITRON [Chen et al., 2023]<br>Med42-v2 [Christophe et al., 2024]<br>TxAgent [Gao et al., 2023]<br>LLaVA-Med [Li et al., 2024]<br>BioMistral [Labrak et al., 2024] |              |       |       |      |     |     |     |     |    |    |    |
|--------------------|---|--------------|-------|-------|------|-----|-----|-----|-----|----|----|----|
| Size               | 100B+<br>MoE  | 100B+<br>MoE | 300B+ | 300B+ | 540B | 70B | 70B | 70B | 70B | 8B | 7B | 7B |
| Web Crawl          | ✓   | ✓            | ✓     | ✓     | ✓    | ✓   | ✓   | ✓   | ✓   | ✓  | ✓  | ✓  |
| QA Training Splits | ✓   | ✓            | ✓     | ✓     | ✓    | ✓   | ✓   | ✓   | ✓   |    | ✓  | ✓  |
| Publications       | ✓   | ✓            | ✓     | ✓     | ✓    | ✓   | ✓   | ✓   | ✓   | ✓  | ✓  | ✓  |
| Clinical Trials    | ✓   | ✓            | ✓     | ✓     | ✓    | ✓   | ✓   | ✓   | ✓   | ✓  |    | ✓  |
| Guidelines         | ✓   | ✓            | ✓     | ✓     | ✓    | ✓   | ✓   | ✓   | ✓   | ✓  |    | ✓  |
| Patient Data       | ✓   | ✓            | ✓     |       |      | ✓   | ✓   |     |     | ✓  | ✓  |    |
| Treatment Outcomes | *   |              |       |       |      |     |     |     |     |    |    |    |

\* Yang et al. [2024] use genomic and outcome data, but not treatment data, from the UK BioBank.

Longitudinal, observational data are the foundation of PH.  
 They are nonexistent in current medical LLMs.

An 87-year-old female with a documented medical history of atrial fibrillation, chronic heart failure with preserved ejection fraction (HFpEF), hypertension, hypokalemia, vitamin D deficiency, and glaucoma is taking the following medications:

- Aspirin 81 mg, once daily
- Diltiazem 240 mg extended-release, once daily
- Furosemide 40 mg, once daily
- Metoprolol tartrate 50 mg, twice daily
- Potassium chloride 20 mEq, once daily

The patient is experiencing moderate pedal edema and has an unstable gait. Medication non-adherence is an ongoing issue. Additionally, a recent echocardiogram indicates that the patient's Left Ventricular Ejection Fraction (LVEF) has worsened to less than 40%. What are the next steps of treatment?

- **Diltiazem:** consider sacubitril-valsartan for further optimization of GDMT.
- **Furosemide:** increase dose to address volume overload and pedal edema.
- **Metoprolol tartrate:** consider succinate for hypertension management - no consideration for pill burden.
- **Added:** SGLT2 inhibitors and spironolactone. No consideration for pill burden.

## Optimizing Medications in Patients with Cardiovascular Disease: A Case Report on Unrecognized Prescribing Cascades in Older Adults

Ha M; Meyer K; Matos A; Turgeon J; \* Chandni Bardolia;

### ▼ Author Information

📅 Sep 03, 2021 | 📖 Volume: 2 | 📄 Issue: 3 | 👁 Views: 3468 | 📄 Downloads: 2325 |

### ► Abstract

**Objective:** Older adults with cardiovascular diseases are especially prone to polypharmacy due to comorbidities and consequent complexity of medication regimens. Prescribing cascades can occur when a side effect is misinterpreted as a new medical condition, leading to the initiation of additional medications without sufficient evidence. This case report illustrates how a healthcare team failure.

**Case Presentation:** A patient with a history of polypharmacy. Her condition worsened due to the need for potassium supplementation, including reducing healthcare team, in order to create a personalized

**Conclusion:** Resolving

are often involved. Deprescribing should be a top priority in medication safety, particularly for older adults with cardiovascular disease. Polypharmacy interventions are necessary to encourage safe use and improve patients' overall wellbeing.

- **Diltiazem:** discontinued. Replaced by losartam due to HFrEF, edema.
- **Furosemide:** reduce dose because of diltiazem → edema cascade.
- **Metoprolol tartrate:** switch to succinate to reduce pill burden (once daily) and maintain outcome.


edema, it can be difficult to recognize as well. The patient's new prescribing cascade and outcomes.

The effects related to diltiazem were deemed no longer appropriate, resulting in the prescribing cascade and outcomes.

Healthcare professionals

1. Sodium-glucose cotransporter-2 inhibitors (SGLT2i). Initiate dapagliflozin or empagliflozin, as these agents have demonstrated

# Where is ground truth?



If human-written text is ground truth, can AI go beyond it?



# AI



# PH

"Use data, methods, and priorities of population health to improve AI"

# Why?

```
graph TD; A["Use data, methods, and priorities of population health to improve AI"] --- B["Faithfully answer PH questions with domain-specific engineering"]; A --- C["Build medical superintelligence with observational data"]
```


Faithfully answer PH questions  
with **domain-specific engineering**

Build medical superintelligence with **observational data**

# Targeting subgroup interventions with AI



## Internal Business User



*"Help me find a subgroup of members who would benefit from this intervention"*

## Language Model with Reasoning, Tool Calling



*Call into software stack, obtain analyses*

## Analytics Software



**TIDE**



**SEPSIS**

CENTER FOR  
SEPSIS EPIDEMIOLOGY & PREVENTION STUDIES



*Internal, read-only database queries*

## Insurance Claims Database



*Call LLM to automate internal processes*

## Internal Business User



*"Help me find a subgroup of members who would benefit from this intervention"*

Language Model with Reasoning, Tool Calling



*Population Health AI*

Analytics Software




**TIDE**



**SEPSIS**

CENTER FOR  
SEPSIS EPIDEMIOLOGY & PREVENTION STUDIES



*AI in Population  
Health*




*Internal, read-only database queries*

Insurance Claims Database

"Use data, methods, and priorities of population health to improve AI"

# Why?





"Use data, methods, and priorities of population health to improve AI"

# How? Where?



**CAB**  
CENTER FOR AI AND BIOMEDICAL INFORMATICS

**Reading Group**

1<sup>st</sup> Monday, every month